Genes, Disease and Therapy Program
The main aim of the Genes, Disease and Therapy Programme is to study the genetic and molecular bases of hereditary diseases and/or immunoinflammatory processes using genomic, transcriptomic and proteomic strategies, in addition to developing new molecular/cellular therapies.
Our programme is multidisciplinary and made up of PIs who are responsible for specialised lines of research in the areas of Human Genetics, Biochemistry, and Molecular and Cell Biology in the field of Biomedicine; their various experimental approaches enrich the transversal approach to the research projects conducted to deepen the knowledge of the bases and pathophysiology of monogenic and complex human genetic diseases, in addition to diseases involving inflammatory processes.
The functional basis of our group includes a scientific-technical training programme for research staff, stimulating the incorporation of new technologies and contributing to an increase in the scientific production of excellence and the transfer of the knowledge acquired and the results obtained in the field of Biomedicine to society. In addition, priority is given to the transfer of results to society through external academic collaborations, with the pharmaceutical and biotechnology industry, and the generation of biomedical utility patents.
Our research group’s aims fall within the framework of challenge 1 of the Horizon 2020 programme “Health, Demographic Change and Wellbeing”, and specifically within objective 1.1 “Understanding health, wellbeing and disease”, sub-section 1.1.2 “Understanding disease”.
Late onset distal myopathy: A new telethoninopathy
Blanco-Palmero VA, Hernández-Laín A, Uriarte-Pérez de Urabayen D, Cantero-Montenegro D, Olivé M, Domínguez-González C
NEUROMUSCULAR DISORDERS. (ISSN/ISBN: 09608966). 29(1): 80-83
Postnatal development of the astrocyte perivascular MLC1/GlialCAM complex defines a temporal window for the gliovascular unit maturation
Gilbert A, Vidal XE, Estevez R, Cohen-Salmon M, Boulay AC
BRAIN STRUCTURE AND FUNCTION. (ISSN/ISBN: 1863-2653).
Orthoxenografts of testicular germ cell tumors demonstrate genomic changes associated with cisplatin resistance and identify PDMP as a re-sensitizing agent.
Piulats JM, Vidal A, García-Rodríguez FJ, Muñoz C, Nadal M, Moutinho C, Martínez-Iniesta M, Mora J, Figueras A, Guinó E, Padullés L, Aytés À, Molleví DG, Puertas S, Martínez-Fernández C, Castillo W, Juliachs M, Moreno V, Muñoz P, Stefanovic M, Pujana MA, Condom E, Esteller M, Germà JR, Capella G, Farré L, Morales A, Viñals F, García-Del-Muro X, Cerón J, Villanueva A
CLINICAL CANCER RESEARCH (ISSN/ISBN: 10780432)
Complement components as promoters of immunological tolerance in dendritic cells
Luque A., Serrano I., Aran J.
SEMINARS IN CELL AND DEVELOPMENTAL BIOLOGY (ISSN/ISBN: 10849521)
Cis-trans proline isomers in the catalytic domain of calcineurin